Event Date/Time: May 17, 2011 End Date/Time: May 20, 2011
Early Registration Date: Feb 25, 2011
Report as Spam


The 5th annual Exploratory Clinical Development World Europe will build on the great success of previous events and brings you a packed agenda, larger speaker panel, more sessions and wider reaching content. You will hear from industry thought leaders from Pfizer, GlaxoSmithKline, AstraZeneca, Takeda, UCB Pharma, Roche, Bayer Schering, Johnson & Johnson, Janssen, Lundbeck, Genentech, Astellas Pharma, Ferring Pharmaceutucals, Grünenthal, Bristol Myers Squibb, Shire, Eli Lilly, Geron Corporation, MHRA, BfArM and FAMHP who will provide you with discussion, summary and knowledge of the best current practices that will help you drive compounds through phase I.

At Exploratory Clinical Development World Europe, the key issues that will be discussed include:
• New paradigms in exploratory clinical development
• Open innovation in pharma
• What is the role of translational science
• Managing the transition between preclinical and first in man studies
• Improving assessment of risk from preclinical screens
• Advancing proof of concept tools and approaches
• Managing risk in early development
• Review of innovative clinical trial design
• Patient involvement and optimal dosing strategy
• Regulatory status and review
• Evaluation of biomarkers in early development
• Improving safety pharmacology data
• Modelling and simulation
• Case study presentations